| 货号 | 17806-50mg |
| 描述 | Dasatinib (Item No. 11498) is a potent inhibitor of receptor and non-receptor tyrosine kinases, including some drug resistant mutant forms.1,2,3,4 It has potential therapeutic value in diseases that are characterized by elevated levels of these kinases, including some forms of cancer and fibrotic disease.1,5,6,7 CAY10697 is an intermediate in the synthesis of dasatinib.8 |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Lombardo, L.J.,Lee, F.Y.,Chen, P., et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825),a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. Journal of Medicinal Chemistry 47(27), 6658-6661 (2004). 2.Das, J.,Chen, P.,Norris, D., et al. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. Journal of Medicinal Chemistry 49(23), 6819-6823 (2006). 3.Davis, M.I.,Hunt, J.P.,Herrgard, S., et al. Comprehensive analysis of kinase inhibitor selectivity. Nat.Biotechnol. 29(11), 1046-1051 (2011). 4.Carter, T.A.,Wodicka, L.M.,Shah, N.P., et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proceedings of the National Academy of Sciences of the United States of America 102(31), 11011-11016 (2005). 5.El-Amm, J.,Freeman, A.,Patel, N., et al. Bone-targeted therapies in metastatic castration-resistant prostate cancer: Evolving paradigms. Prostate Cancer 2013, 1-10 (2013). 6.Distler, J.H.W. and Distler, O. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology 47, 10-11 (2008). 7.McFarland, K.L. and Wetzstein, G.A. Chronic myeloid leukemia therapy: Focus on second-generation tyrosine kinase inhibitors. Cancer Control 16(2), 132-140 (2009). 8.Deadman, B.J.,Hopkin, M.D.,Baxendale, I.R., et al. The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib. Organic & Biomolecular Chemistry 11, 1766-1800 (2013). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 394.3 |
| 分子式 | C16H13Cl2N5OS |
| CAS号 | 302964-08-5 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |